SKIN CARE 67
difference in mean a* parameter between Product A treated skin and Product B treated skin was statistically significantly different at week 10 (P<0.03) indicating that the side of the face treated with Product A was statistically significantly less red than the half of the face treated with Product B. Both sides of the face increased
between baseline and week 10 by a similar amount. There were statistically significant
changes (p<0.05) for the mean b* (blue/yellow) (Table 8) parameter between baseline and week 10 for Product A and Product B, indicating a statistically significant change in overall skin colour towards the yellow hue. We attribute this to sun exposure increasing melanin in the skin as the study was conducted over the summer months.
Corneometer data The side of the face treated with Product A showed an increase in mean Corneometer value by 7% between baseline and week 10, whereas the side of the face treated with Product B showed essentially no change in mean Corneometer value between baseline and week 10 (Fig 5). Additionally, the difference in mean
Corneometer value between the side of the face treated with Product A and Product B at week 10 was 16%. There were statistically significant
changes (p<0.05) for the mean Corneometer value between baseline and weeks 4, 8 and week 10 for Product A, indicating a statistically significant increase in overall skin moisturisation. In addition, the difference in mean Corneometer value between Product A treated skin and
Table 8: Blue/Yellow A
T0 Mean
Median SD
Min max
B Mean
Median SD
Min max
15.59719 15.427
2.832322 10.028 20.736 T0
15.6345 15.201
2.78071 9.716
20.372 than the side treated with Product B. T10 16.33 16.478
2.822418 10.62
21.666 T10
16.32826 16.056
2.612853 11.842 21.568
Product B treated skin was highly statistically significant at week 10 (P<0.001), indicating that the side of the face treated with Product A was significantly more moisturised than the side of the face treated with Product B.
Conclusion The primary objective of the study was to compare a facial formulation containing Biollagen from Jland Biotech against a placebo formulation. Several statistically significant differences were observed between the side of the face treated with Product A and Product B, in favour of Product A. They were: l Change in image analysis parameter for Pores between baseline and week 10, but not for Product B
l Increase in latent (unseen) UV spots for the Product B treated side of the face but not for the side treated with Product A.
l Chromameter analysis of skin colour and lightness showed that the side of the face treated with Product A was 2% lighter
l The chromameter parameter a*, which measures colour on the green to red axis, showed a decrease in redness for the side of the face treated with Product A and an increase in redness for the Product B treated side over the study.
l Moisturisation of the skin was shown to increase for the side of the face treated with Product A from week 4 onwards, whereas there was no change for the side treated with Product B. At week 10, there was a 16% higher mean corneometer value for Product A than Product B, a highly statistically significant difference.
l From the blind assessment of paired, randomized images, there was a statistically significant (p=0.004) positive change in skin appearance between 0 and 10 weeks for the active treated side of the face, compared to the placebo treated side. From the data obtained in this double
blind, placebo-controlled study, we conclude that there are significant benefits in terms of moisturisation and preventing accelerated skin ageing, particularly maintaining a lighter skin tone and preventing future visible ageing signs for skin treated with Biollagen, compared to the placebo formulation. Of particular note also, are the results of the blind scoring of skin appearance from paired, randomized images. These support the data obtained from the instrumental analysis by demonstrating that the active formulation was able to lead to perceivably improved skin condition with regular use, whereas the placebo treated side was seen to worsen in appearance.
PC
November 2020
PERSONAL CARE ASIA PACIFIC
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
